XOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum

[GlobeNewswire] – BERKELEY, Calif. — XOMA Corporation , a leader in the discovery and development of therapeutic antibodies, announced today gevokizumab, the Company’s IL-1 beta modulating antibody, has been granted Orphan … more

View todays social media effects on XOMA

View the latest stocks trending across Twitter. Click to view dashboard

See who XOMA is hiring next, click here to view